.png "NovoCure Ltd (NASDAQ: NVCR)")
Mizuho Securities analyst Difei Yang maintained a Buy rating on NovoCure Ltd (NVCR) today and set a price target of $63. The company’s shares closed yesterday at $48.16.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.4% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NovoCure Ltd with a $61 average price target, a 26.7% upside from current levels. In a report issued on March 1, Wedbush also maintained a Buy rating on the stock with a $59 price target.
See today’s analyst top recommended stocks >>
Based on NovoCure Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $15.63 million. In comparison, last year the company had a GAAP net loss of $10.95 million.
Based on the recent corporate insider activity of 102 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.
